Home » Singapore Outlines Process to Register Biosimilars
Singapore Outlines Process to Register Biosimilars
September 17, 2009
Drugmakers seeking to register a biosimilar product in Singapore should provide complete information on the development, control and manufacture of the drug and its active ingredient, a new guidance says. Includes the full text of Singapore Biosimilars Registration Guidance.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor